biosimilars
Samsung Bioepis & Biogen receive positive CHMP opinion for ranibizumab biosimilar
June 28, 2021Sales and Marketing EC, EMA, EU, biosimilars
Samsung Bioepis and Biogen have announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has adopted a …
Biosimilars and Brexit: What’s in store for UK’s biosimilar market?
June 2, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biosimilars, brexit
It’s been 15 years since the first biosimilar entered the market, and the impact of these drugs on the healthcare …
Exclusive interview: Samsung Bioepis’ Sang-Jin Pak on the rise of biosimilars
December 2, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Samsung Bioepis, biosimilars, pharma
Following on from our focus on biosimilars in our feature last week, you can read Nikhil Patel’s interview with Sang-Jin …
Europe approves first subcutaneous version of biosimilar infliximab
November 26, 2019Manufacturing and Production, Sales and Marketing arthritis, biosimilars, celltrion, infliximab, pharma
The European Commission has chosen to authorise Celltrion Healthcare’s Remsima SC, a biosimilar of infliximab and the first subcutaneous formulation …
The coming age of biosimilars
November 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biosimilars, feature, pharma
With more and more biosimilars securing approval and the sheer potential value they have to offer for healthcare systems around …
Pfizer to combine off-patent drug unit Upjohn with Mylan
July 30, 2019Manufacturing and Production M&A, MA, Mylan, Pfizer, Upjohn, biosimilars, generics, mergers
Pfizer’s off-patent drug unit Upjohn is combining with Mylan to create a new global pharmaceutical company focused on the low-price …
Humira biosimilar from Samsung Bioepis and MSD wins marketing authorisation in the US
July 24, 2019Research and Development, Sales and Marketing AbbVie, Humira, MSD, Samsung Bioepis, biosimilars, pharma
It’s another victory for MSD as the US drugmaker announced that its biosimilar version of AbbVie’s Humira – the world’s …
FDA approves Pfizer’s biosimilar version of Genentech’s Rituxan
July 24, 2019Research and Development FDA, Pfizer, Rituxan, Ruxience, biosimilars, pharma
Pfizer has seen Ruxience, its biosimilar version of Genentech’s Rituxan (rituximab), approved by the FDA in the treatment of non-Hodgkin …
Top Ten most popular articles on Pharmafile.com of 2018!
December 21, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Business, biosimilars, brexit, pharma, top 10
Brexit, business and biosimilars, seemed to be the three themes of 2018. As Brexit negotiations reached a stalemate the pharmaceutical …
Top Ten most popular articles on Pharmafile.com this week
November 30, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, Immuno Biotech, NHS, Roche, autism, biosimilars, pharma, top ten
We’ve come to the end of November, and with only one month of the year left to go, the industry …
FDA approves first Rituxan biosimilar courtesy of Teva and Celltrion
November 29, 2018Sales and Marketing FDA, Genentech, Rituxan, Roche, Teva, Truxima, biosimilars, celltrion
The FDA has announced the first US approval of a biosimilar version of Genentech’s Rituxan (rituximab), awarding marketing approval to …
Pegfilgrastim greenlight marks eighth biosimilar approval in Europe for Sandoz
November 27, 2018Manufacturing and Production, Sales and Marketing Amgen, Neulasta, Sanofi, Ziextenzo, biosimilars, pegfilgrastim, pharma
The European Commission has chosen to grant marketing authorisation to Ziextenzo, Sandoz’s biosimilar version of pegfilgrastim, better known as Amgen’s …
NHS to save £300 million by switching to Humira biosimilars
November 27, 2018Manufacturing and Production, Sales and Marketing AbbVie, Humira, Mylan, NHS, Sandoz, adalimumab, biosimilars, pharrma
NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of …
German health minister Jens Spahn calls for faster adoption of biosimilars
November 14, 2018Research and Development AbbVie, Germany, biosimilars, jens Spahn
Germany’s health minister Jens Spahn has called for faster uptake of biosimilars in an effort to cut the cost of …
Working Life: Philippe Bastide, Head of Biosimilars, Mundipharma
November 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Mundipharma, Philippe Bastide, biosimilars, leukaemia
“Don’t conform to what people want – take risks. The people who make a big difference are the ones who …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
